Table 1 Main characteristics of the studies included in this meta-analysis
Study | Year | Patient source | Antibody type | Antibody dilution | Number of patients | Tumor stage | Method and isoforms | Cutoff value | HR Source | Outcome | NOS score |
|---|---|---|---|---|---|---|---|---|---|---|---|
Kong | 2020 | China | Beijing Bioss Biotech | 1:100 | 37 | I, II, III | IHC |  ≥ 2a | SC | OS, CPF | 6 |
Mohamed | 2019 | Egypt | Santa Cruz | 1:100 | 66 | II, III | IHC |  > 30%b | NA | CPF | 6 |
Wu | 2019 | China | Santa Cruz | 1:100 | 53 | I, II, III | IHC |  ≥ 4a | COX | OS, CPF | 7 |
Liu | 2017 | China | Santa Cruz | NA | 84 | I, II, III | IHC |  ≥ 1a | COX | OS, CPF | 7 |
Lei | 2015 | China | Abcam | 1:150 | 32 | I, II, III | IHC |  > 3a | NA | CPF | 6 |
Zhao | 2015 | China | NA | NA | 153 | I, II, III | IHC |  ≥ 4a | SC | OS, CPF | 8 |
Baptista | 2014 | Brazil | Dako | 1:100 | 50 | I, IIA, IIB | IHC |  > 30%b | SC | OS, DFS, CPF | 8 |
Becker | 2013 | Brazil | Dako | 1:50 | 27 | IIB III | IHC |  > 30%b | NA | CPF | 6 |
Lammli | 2012 | USA | Santa Cruz | NA | 54 | NA | IHC |  ≥ 20%b | NA | CPF | 6 |
Chen | 2012 | China | Santa Cruz | 1:200 | 49 | IIA, IIB, III | IHC | NA | SC | DFS, CPF | 9 |
Zhou | 2011 | China | Santa Cruz | 1:200 | 65 | IIA, IIB, III | IHC |  ≥ 10%b | NA | CPF | 6 |
Lin | 2011 | China | FuZhou JingXing Corporation | NA | 56 | II III | IHC |  ≥ 10%b | SC | OS, CPF | 8 |
Lugowska | 2011 | Poland | Santa Cruz | 4:2000 | 91 | IIB, III | IHC |  > 50%b | COX | OS, CPF | 8 |
Abdeen | 2009 | USA | NA | NA | 48 | IIB, III | IHC |  ≥ 2pointsc | NA | CPF | 7 |
Mizobuchi | 2008 | USA | Santa Cruz | 1:200 | 48 | NA | IHC |  ≥ 1, intensity of staining | NA | CPF | 6 |
Huang | 2008 | China | Santa Cruz | 1:100 | 31 | I, IIA, IIB | IHC |  ≥ 1, intensity of staining | NA | CPF | 6 |
Park | 2008 | Korea | Zymed Lab | 1:100 | 35 | NA | IHC |  > 30%b | NA | CPF | 6 |
Charity | 2006 | England | BD Biosciences Pharmingen | NA | 53 | I, II, III | IHC |  ≥ 25%b | COX | OS, DFS, CPF | 6 |
Oda | 2006 | Japan | Santa Cruz | 1:500 | 30 | NA | IHC | IRS ≥ 2 + with focal to diffuse distributions | SC | OS, CPF | 8 |
Jung | 2005 | Korea | Santa Cruz | 1:200 | 25 | NA | IHC |  > 2 + , number of new vessel | NA | CPF | 7 |
Kaya | 2000 | Jpan | Santa Cruz | 1:200 | 27 | I, II, III | IHC |  > 30% b | SC | OS, DFS, CPF | 9 |
Lee | 1999 | Japan | – | – | 30 | NA | RT-PCR | – | SC | OS, CPF | 6 |